Skip to main content Accessibility help
×
×
Home

Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases

  • Peter Celec (a1) (a2) (a3), Barbora Vlková (a1), Lucia Lauková (a1), Janka Bábíčková (a1) (a4) and Peter Boor (a1) (a5)...

Abstract

Cell-free DNA (cfDNA) is present in various body fluids and originates mostly from blood cells. In specific conditions, circulating cfDNA might be derived from tumours, donor organs after transplantation or from the foetus during pregnancy. The analysis of cfDNA is mainly used for genetic analyses of the source tissue —tumour, foetus or for the early detection of graft rejection. It might serve also as a nonspecific biomarker of tissue damage in critical care medicine. In kidney diseases, cfDNA increases during haemodialysis and indicates cell damage. In patients with renal cell carcinoma, cfDNA in plasma and its integrity is studied for monitoring of tumour growth, the effects of chemotherapy and for prognosis. Urinary cfDNA is highly fragmented, but the technical hurdles can now be overcome and urinary cfDNA is being evaluated as a potential biomarker of renal injury and urinary tract tumours. Beyond its diagnostic application, cfDNA might also be involved in the pathogenesis of diseases affecting the kidneys as shown for systemic lupus, sepsis and some pregnancy-related pathologies. Recent data suggest that increased cfDNA is associated with acute kidney injury. In this review, we discuss the biological characteristics, sources of cfDNA, its potential use as a biomarker as well as its role in the pathogenesis of renal and urinary diseases.

Copyright

Corresponding author

*Corresponding author: Peter Celec, Faculty of Medicine, Institute of Molecular Biomedicine, Comenius University, Sasinkova 4, 811 08 Bratislava, Slovakia. E-mail: petercelec@gmail.com

References

Hide All
1. Mandel, P. and Metais, P. (1948) Les acides nucleiques du plasma sanguin chez l'homme. Comptes Rendus Des Seances De La Societe De Biologie Et De Ses Filiales 142, 241-243
2. Steinman, C.R. (1975) Free DNA in serum and plasma from normal adults. The Journal of Clinical Investigation 56, 512-515
3. Steinman, C.R. and Ackad, A. (1977) Appearance of circulating DNA during hemodialysis. American Journal of Medicine 62, 693-697
4. Fournie, G.J. et al. (1989) Plasma DNA in patients undergoing hemodialysis or hemofiltration: cytolysis in artificial kidney is responsible for the release of DNA in circulation. American Journal of Nephrology 9, 384-391
5. Zhong, X.Y. et al. (2000) Fluctuation of maternal and fetal free extracellular circulatory DNA in maternal plasma. Obstetrics & Gynecology 96, 991-996
6. Rumore, P. et al. (1992) Haemodialysis as a model for studying endogenous plasma DNA: oligonucleosome-like structure and clearance. Clinical and Experimental Immunology 90, 56-62
7. Garcia Moreira, V. et al. (2006) Increase in and clearance of cell-free plasma DNA in hemodialysis quantified by real-time PCR. Clinical Chemistry and Laboratory Medicine 44, 1410-1415
8. Avriel, A. et al. (2014) Admission cell free DNA levels predict 28-day mortality in patients with severe sepsis in intensive care. PLoS ONE 9, e100514
9. Lui, Y.Y. et al. (2002) Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clinical Chemistry 48, 421-427
10. Snyder, T.M. et al. (2011) Universal noninvasive detection of solid organ transplant rejection. Proceedings of the National Academy of Sciences of the United States of America 108, 6229-6234
11. Fleischhacker, M. and Schmidt, B. (2007) Circulating nucleic acids (CNAs) and cancer – a survey. Biochimica et Biophysica Acta 1775, 181-232
12. De Vlaminck, I. et al. (2014) Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Science Translational Medicine 6, 241- 277
13. Allam, R. et al. (2014) Extracellular histones in tissue injury and inflammation. Journal of Molecular Medicine (Berlin) 92, 465-472
14. Breitbach, S., Tug, S. and Simon, P. (2012) Circulating cell-free DNA: an up-coming molecular marker in exercise physiology. Sports Medicine 42, 565-586
15. Jeong da, W. et al. (2015) Effect of blood pressure and glycemic control on the plasma cell-free DNA in hemodialysis patients. Kidney Research and Clinical Practice 34, 201-206
16. Lui, Y.Y. et al. (2003) Origin of plasma cell-free DNA after solid organ transplantation. Clinical Chemistry 49, 495-496
17. Beck, J. et al. (2015) Donor-derived cell-free DNA is a novel universal biomarker for allograft rejection in solid organ transplantation. Transplantation Proceedings 47, 2400-2403
18. Lo, Y.M. and Chiu, R.W. (2007) Prenatal diagnosis: progress through plasma nucleic acids. Nature Reviews Genetics 8, 71-77
19. Haghiac, M. et al. (2012) Increased death of adipose cells, a path to release cell-free DNA into systemic circulation of obese women. Obesity (Silver Spring) 20, 2213-2219
20. Chan, K.C. et al. (2004) Size distributions of maternal and fetal DNA in maternal plasma. Clinical Chemistry 50, 88-92
21. Schwarzenbach, H., Hoon, D.S. and Pantel, K. (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nature Reviews. Cancer 11, 426-437
22. Carlson, J.A. et al. (1988) Glomerular localization of circulating single-stranded DNA in mice. Dependence on the molecular weight of DNA. Journal of Autoimmunity 1, 231-241
23. Li, Y. et al. (2006) Cell-free DNA in maternal plasma: is it all a question of size? Annals of the New York Academy of Sciences 1075, 81-87
24. Chan, R.W. et al. (2014) Plasma DNA aberrations in systemic lupus erythematosus revealed by genomic and methylomic sequencing. Proceedings of the National Academy of Sciences of the United States of America 111, E5302E5311
25. Cherepanova, A.V. et al. (2008) Deoxyribonuclease activity and circulating DNA concentration in blood plasma of patients with prostate tumors. Annals of the New York Academy of Sciences 1137, 218-221
26. Stephan, F. et al. (2014) Cooperation of factor VII-activating protease and serum DNase I in the release of nucleosomes from necrotic cells. Arthritis and Rheumatology 66, 686-693
27. Nadano, D., Yasuda, T. and Kishi, K. (1993) Measurement of deoxyribonuclease I activity in human tissues and body fluids by a single radial enzyme-diffusion method. Clinical Chemistry 39, 448-452
28. Gauthier, V.J., Tyler, L.N. and Mannik, M. (1996) Blood clearance kinetics and liver uptake of mononucleosomes in mice. Journal of Immunology 156, 1151-1156
29. Emlen, W. and Mannik, M. (1984) Effect of DNA size and strandedness on the in vivo clearance and organ localization of DNA. Clinical and Experimental Immunology 56, 185-192
30. Du Clos, T.W. et al. (1999) Chromatin clearance in C57Bl/10 mice: interaction with heparan sulphate proteoglycans and receptors on Kupffer cells. Clinical and Experimental Immunology 117, 403-411
31. Lo, Y.M.D. et al. (1999) Rapid clearance of fetal DNA from maternal plasma. American Journal of Human Genetics 64, 218-224
32. Chused, T.M., Steinberg, A.D. and Talal, N. (1972) The clearance and localization of nucleic acids by New Zealand and normal mice. Clinical and Experimental Immunology 12, 465-476
33. Jylhava, J. et al. (2012) A genome-wide association study identifies UGT1A1 as a regulator of serum cell-free DNA in young adults: the cardiovascular risk in young Finns study. PLoS ONE 7, e35426
34. Williams, J.A. et al. (2002) Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metabolism and Disposition 30, 1266-1273
35. Korabecna, M. et al. (2008) Cell-free plasma DNA during peritoneal dialysis and hemodialysis and in patients with chronic kidney disease. Annals of the New York Academy of Sciences 1137, 296-301
36. Yu, S.C. et al. (2013) High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing. Clinical Chemistry 59, 1228-1237
37. Anker, P. et al. (1999) Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer and Metastasis Reviews 18, 65-73
38. Tamkovich, S.N. et al. (2006) Circulating DNA and DNase activity in human blood. Annals of the New York Academy of Sciences 1075, 191-196
39. Papadopoulou, E. et al. (2004) Cell-free DNA and RNA in plasma as a new molecular marker for prostate cancer. Oncology Research 14, 439-445
40. Cedervall, J. et al. (2015) Neutrophil extracellular traps accumulate in peripheral blood vessels and compromise organ function in tumor-bearing animals. Cancer Research 75, 2653-2662
41. Boddy, J.L. et al. (2006) The role of cell-free DNA size distribution in the management of prostate cancer. Oncology Research 16, 35-41
42. Chen, H. et al. (2012) Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma. Pathology 44, 318-324
43. Feng, J. et al. (2013) Plasma cell-free DNA and its DNA integrity as biomarker to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate-specific antigen. International Urology and Nephrology 45, 1023-1028
44. Su, Y.H. et al. (2008) Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps. Annals of the New York Academy of Sciences 1137, 197-206
45. Chan, K.C. et al. (2013) Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proceedings of the National Academy of Sciences of the United States of America 110, 18761-18768
46. Chan, K.C. et al. (2013) Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clinical Chemistry 59, 211-224
47. Thierry, A.R. et al. (2014) Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Natural Medicines 20, 430-435
48. Janku, F. et al. (2014) BRAF v600e mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Oncotarget 5, 3607-3610
49. Shi, X.Q. et al. (2017) Dynamic tracing for epidermal growth factor receptor mutations in urinary circulating DNA in gastric cancer patients. Tumour Biology 39, 1010428317691681
50. Chen, S. et al. (2017) Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs. Clinical & Translational Oncology 19, 332-340
51. Perego, R.A. et al. (2008) Concentration and microsatellite status of plasma DNA for monitoring patients with renal carcinoma. European Journal of Cancer 44, 1039-1047
52. de Martino, M. et al. (2012) Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. Cancer 118, 82-90
53. Wan, J. et al. (2013) Monitoring of plasma cell-free DNA in predicting postoperative recurrence of clear cell renal cell carcinoma. Urologia Internationalis 91, 273-278
54. Gang, F. et al. (2010) Prediction of clear cell renal cell carcinoma by integrity of cell-free DNA in serum. Urology 75, 262-265
55. Hauser, S. et al. (2010) Cell-free circulating DNA: diagnostic value in patients with renal cell cancer. Anticancer Research 30, 2785-2789
56. Shaked, G. et al. (2014) Recent advances in clinical applications of circulating cell-free DNA integrity. BioMed Research International 45, 6-11
57. Lu, H. et al. (2016) Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients. Clinica Chimica Acta 452, 109-119
58. Hauser, S. et al. (2013) Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study. Anticancer Research 33, 4651-4656
59. Feng, G. et al. (2013) Quantification of plasma cell-free DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma. Disease Markers 34, 105-111
60. Ellinger, J. et al. (2012) Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies. Urologic Oncology 30, 509-515
61. Hoque, M.O. et al. (2004) Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Research 64, 5511-5517
62. Urakami, S. et al. (2006) Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clinical Cancer Research 12, 6989-6997
63. Hoque, M.O. et al. (2006) Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. Journal of the National Cancer Institute 98, 996-1004
64. von Knobloch, R. et al. (2001) Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. International Journal of Cancer 94, 67-72
65. Szarvas, T. et al. (2007) Deletion analysis of tumor and urinary DNA to detect bladder cancer: urine supernatant versus urine sediment. Oncology Reports 18, 405-409
66. Little, B. et al. (2005) Use of polymerase chain reaction analysis of urinary DNA to detect bladder carcinoma. Urologic Oncology 23, 102-107
67. Chang, H.W. et al. (2007) Urinary cell-free DNA as a potential tumor marker for bladder cancer. International Journal of Biological Markers 22, 287-294
68. Zancan, M. et al. (2009) Evaluation of cell-free DNA in urine as a marker for bladder cancer diagnosis. International Journal of Biological Markers 24, 147-155
69. Casadio, V. et al. (2013) Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: a pilot study. BioMed Research International 2013, 270457
70. Casadio, V. et al. (2013) Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data. Urologic Oncology 31, 1744-1750
71. Zhao, A. et al. (2015) Cell-free RNA content in urine as a possible molecular diagnostic tool for clear cell renal cell carcinoma. International Journal of Cancer 136, 2610-2615
72. Salvi, S. et al. (2015) Urine cell-free DNA integrity analysis for early detection of prostate cancer patients. Disease Markers 2015, 574120
73. Lo, Y.M. et al. (1998) Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients. Lancet 351, 1329-1330
74. Zhong, X.Y. et al. (2001) Cell-free DNA in urine: a marker for kidney graft rejection, but not for prenatal diagnosis? Annals of the New York Academy of Sciences 945, 250-257
75. Adamek, M. et al. (2016) A fast and simple method for detecting and quantifying donor-derived cell-free DNA in sera of solid organ transplant recipients as a biomarker for graft function. Clinical Chemistry and Laboratory Medicine 54, 1147-1155
76. Martins, P.N. et al. (2005) Quantification of donor-derived DNA in serum: a new approach of acute rejection diagnosis in a rat kidney transplantation model. Transplantation Proceedings 37, 87-88
77. Garcia Moreira, V. et al. (2009) Cell-free DNA as a noninvasive acute rejection marker in renal transplantation. Clinical Chemistry 55, 1958-1966
78. Sigdel, T.K. and Sarwal, M.M. (2012) Cell-free DNA as a measure of transplant injury. Clinical Transplants 201-205
79. Lee, H. et al. (2017) Evaluation of digital PCR as a technique for monitoring acute rejection in kidney transplantation. Genomics and Informatics 15, 2-10
80. Cheng, T.H.T. et al. (2017) Genomewide bisulfite sequencing reveals the origin and time-dependent fragmentation of urinary cfDNA. Clinical Biochemistry 50, 496-501
81. Bloom, R.D. et al. (2017) Cell-free DNA and active rejection in kidney allografts. Journal of the American Society of Nephrology 28, 2221-2232
82. Gielis, E.M. et al. (2015) Cell-free DNA: an upcoming biomarker in transplantation. American Journal of Transplantation 15, 2541-2551
83. Oellerich, M. et al. (2016) Graft-derived cell-free DNA as a marker of transplant graft injury. Therapeutic Drug Monitoring 38(Suppl 1), S75S79
84. Antonatos, D. et al. (2006) Cell-free DNA levels as a prognostic marker in acute myocardial infarction. Annals of the New York Academy of Sciences 1075, 278-281
85. Destouni, A. et al. (2009) Cell-free DNA levels in acute myocardial infarction patients during hospitalization. Acta Cardiologica 64, 51-57
86. Shimony, A. et al. (2010) Cell free DNA detected by a novel method in acute ST-elevation myocardial infarction patients. Acute Cardiac Care 12, 109-111
87. Huang, C.H. et al. (2012) Circulating cell-free DNA levels correlate with postresuscitation survival rates in out-of-hospital cardiac arrest patients. Resuscitation 83, 213-218
88. Gornik, I. et al. (2014) Prognostic value of cell-free DNA in plasma of out-of-hospital cardiac arrest survivors at ICU admission and 24 h post-admission. Resuscitation 85, 233-237
89. Zaravinos, A. et al. (2011) Levosimendan reduces plasma cell-free DNA levels in patients with ischemic cardiomyopathy. Journal of Thrombosis and Thrombolysis 31, 180-187
90. Boyko, M. et al. (2011) Cell-free DNA – a marker to predict ischemic brain damage in a rat stroke experimental model. Journal of Neurosurgical Anesthesiology 23, 222-228
91. Macher, H. et al. (2012) Role of early cell-free DNA levels decrease as a predictive marker of fatal outcome after severe traumatic brain injury. Clinica Chimica Acta 414, 12-17
92. Ohayon, S. et al. (2012) Cell-free DNA as a marker for prediction of brain damage in traumatic brain injury in rats. Journal of Neurotrauma 29, 261-267
93. Ren, B. et al. (2013) Is plasma cell-free DNA really a useful marker for diagnosis and treatment of trauma patients? Clinica Chimica Acta 424, 109-113
94. Chiu, T.W. et al. (2006) Plasma cell-free DNA as an indicator of severity of injury in burn patients. Clinical Chemistry and Laboratory Medicine 44, 13-17
95. Shoham, Y., Krieger, Y. and Perry, Z.H. (2014) Admission cell free DNA as a prognostic factor in burns: quantification by use of a direct rapid fluorometric technique. BioMed Research International 2014, 306580
96. Jylhava, J. et al. (2012) Circulating cell-free DNA is associated with mortality and inflammatory markers in nonagenarians: the vitality 90+ study. Experimental Gerontology 47, 372-378
97. Zhong, X.Y. et al. (2007) Increased concentrations of antibody-bound circulatory cell-free DNA in rheumatoid arthritis. Clinical Chemistry 53, 1609-1614
98. Shin, C. et al. (2008) Increased cell-free DNA concentrations in patients with obstructive sleep apnea. Psychiatry and Clinical Neurosciences 62, 721-727
99. Ye, L. et al. (2010) Quantification of circulating cell-free DNA in the serum of patients with obstructive sleep apnea-hypopnea syndrome. Lung 188, 469-474
100. El Tarhouny, S.A. et al. (2010) Assessment of cell-free DNA with microvascular complication of type II diabetes mellitus, using PCR and ELISA. Nucleosides Nucleotides & Nucleic Acids 29, 228-236
101. Arnalich, F., Lopez-Collazo, E. and Montiel, C. (2011) Diagnostic potential of circulating cell-free DNA in patients needing mechanical ventilation: promises and challenges. Critical Care 15, 187
102. Okkonen, M. et al. (2011) Plasma cell-free DNA in patients needing mechanical ventilation. Critical Care 15, R196
103. Ramos, M.V. et al. (2016) Induction of neutrophil extracellular traps in shiga toxin-associated hemolytic uremic syndrome. Journal of Innate Immunity 8, 400-411
104. Yoshida, M. et al. (2016) Myeloperoxidase anti-neutrophil cytoplasmic antibody affinity is associated with the formation of neutrophil extracellular traps in the kidney and vasculitis activity in myeloperoxidase anti-neutrophil cytoplasmic antibody-associated microscopic polyangiitis. Nephrology (Carlton) 21, 624-629
105. Nakazawa, D. et al. (2014) Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA-associated microscopic polyangiitis. Journal of the American Society of Nephrology 25, 990-997
106. Wang, H. et al. (2016) Circulating level of neutrophil extracellular traps is not a useful biomarker for assessing disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. PLoS ONE 11, e0148197
107. Bossola, M. et al. (2009) Circulating bacterial-derived DNA fragments and markers of inflammation in chronic hemodialysis patients. Clinical Journal of the American Society of Nephrology 4, 379-385
108. Kwan, B.C. et al. (2013) Circulating bacterial-derived DNA fragments as a marker of systemic inflammation in peritoneal dialysis. Nephrology Dialysis Transplantation 28, 2139-2145
109. Hemmi, H. et al. (2000) A toll-like receptor recognizes bacterial DNA. Nature 408, 740-745
110. Lood, C. et al. (2016) Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Natural Medicines 22, 146-153
111. Zachariah, R. et al. (2009) Circulating cell-free DNA as a potential biomarker for minimal and mild endometriosis. Reproductive Biomedicine Online 18, 407-411
112. Zhang, Q. et al. (2010) Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464, 104-107
113. Nakahira, K. et al. (2013) Circulating mitochondrial DNA in patients in the ICU as a marker of mortality: derivation and validation. PLoS Medicine 10, e1001577; discussion e77
114. Sursal, T. et al. (2013) Plasma bacterial and mitochondrial DNA distinguish bacterial sepsis from sterile systemic inflammatory response syndrome and quantify inflammatory tissue injury in nonhuman primates. Shock 39, 55-62
115. Huttunen, R. et al. (2011) Fatal outcome in bacteremia is characterized by high plasma cell free DNA concentration and apoptotic DNA fragmentation: a prospective cohort study. PLoS ONE 6, e21700
116. Forsblom, E. et al. (2014) High cell-free DNA predicts fatal outcome among Staphylococcus aureus bacteraemia patients with intensive care unit treatment. PLoS ONE 9, e87741
117. Dwivedi, D.J. et al. (2012) Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. Critical Care 16, R151
118. Clementi, A. et al. (2016) The role of cell-free plasma DNA in critically Ill patients with sepsis. Blood Purification 41, 34-40
119. Botezatu, I. et al. (2000) Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clinical Chemistry 46, 1078-1084
120. Shekhtman, E.M. et al. (2009) Optimization of transrenal DNA analysis: detection of fetal DNA in maternal urine. Clinical Chemistry 55, 723-729
121. Hung, E.C.W. et al. (2009) Presence of donor-derived DNA and cells in the urine of sex-mismatched hematopoietic stem cell transplant recipients: implication for the transrenal hypothesis. Clinical Chemistry 55, 715-722
122. Garcia Moreira, V. et al. (2009) Elevated transrenal DNA (cell-free urine DNA) in patients with urinary tract infection compared to healthy controls. Clinical Biochemistry 42, 729-731
123. Bret, L. et al. (1990) Extracellular DNA in blood and urine as a potential marker for cytotoxicity and nephrotoxicity in the mouse. Renal Failure 12, 133-139
124. Bret, L. et al. (1993) Kidney tubule enzymes and extracellular DNA in urine as markers for nephrotoxicity in the Guinea pig. Enzyme and Protein 47, 27-36
125. Vaara, S.T. et al. (2016) Urinary biomarkers indicative of apoptosis and acute kidney injury in the critically Ill. PLoS ONE 11, e0149956
126. Cooke, M.S., Henderson, P.T. and Evans, M.D. (2009) Sources of extracellular, oxidatively-modified DNA lesions: implications for their measurement in urine. Journal of Clinical Biochemistry and Nutrition 45, 255-270
127. Outinen, T.K. et al. (2012) Plasma cell-free DNA levels are elevated in acute Puumala hantavirus infection. PLoS ONE 7, e31455
128. Petrucci, R. et al. (2014) Use of transrenal DNA for the diagnosis of extrapulmonary tuberculosis in children: a case of tubercular otitis media. Journal of Clinical Microbiology 53, 336-338
129. Whitaker, R.M. et al. (2015) Urinary mitochondrial DNA is a biomarker of mitochondrial disruption and renal dysfunction in acute kidney injury. Kidney International 88, 1336-1344
130. Eirin, A. et al. (2016) Urinary mitochondrial DNA copy number identifies chronic renal injury in hypertensive patients. Hypertension 68, 401-410
131. Koffler, D. et al. (1973) The occurrence of single-stranded DNA in the serum of patients with systemic lupus erythematosus and other diseases. The Journal of Clinical Investigation 52, 198-204
132. Izui, S. et al. (1977) Features of systemic lupus erythematosus in mice injected with bacterial lipopolysaccharides: identificantion of circulating DNA and renal localization of DNA-anti-DNA complexes. Journal of Experimental Medicine 145, 1115-1130
133. Bruneau, C. and Benveniste, J. (1979) Circulating DNA:anti-DNA complexes in systemic lupus erythematosus. Detection and characterization by ultracentrifugation. The Journal of Clinical Investigation 64, 191-198
134. Williams, D.G. and Adu, D. (1980) Circulating DNA-anti-DNA complexes in lupus nephritis and idiopathic nephritis. Proceedings of the European Dialysis and Transplant Association 17, 629-636
135. Adu, D., Dobson, J. and Williams, D.G. (1981) DNA-anti-DNA circulating complexes in the nephritis of systemic lupus erythematosus. Clinical and Experimental Immunology 43, 605-614
136. McCoubrey-Hoyer, A., Okarma, T.B. and Holman, H.R. (1984) Partial purification and characterization of plasma DNA and its relation to disease activity in systemic lupus erythematosus. American Journal of Medicine 77, 23-34
137. Pisetsky, D.S. and Jiang, N. (2006) The generation of extracellular DNA in SLE: the role of death and sex. Scandinavian Journal of Immunology 64, 200-204
138. Linkermann, A. et al. (2014) Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nature Reviews. Immunology 14, 759-767
139. Barnado, A., Crofford, L.J. and Oates, J.C. (2016) At the bedside: neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases. Journal of Leukocyte Biology 99, 265-278
140. Gupta, S. and Kaplan, M.J. (2016) The role of neutrophils and NETosis in autoimmune and renal diseases. Nature Reviews Nephrology 12, 402-413
141. Hakkim, A. et al. (2010) Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proceedings of the National Academy of Sciences 107, 9813-9818
142. Camicia, G. et al. (2015) Association between severe disease course and nephritis with Q222R polymorphism in DNAse I gene among lupus patients: an Argentine multicenter study. Acta Reumatologica Portuguesa 41, 138-144
143. Gajic-Veljic, M. et al. (2015) Importance of low serum DNase I activity and polyspecific anti-neutrophil cytoplasmic antibodies in propylthiouracil-induced lupus-like syndrome. Rheumatology (Oxford) 54, 2061-2070
144. Leffler, J. et al. (2012) Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. Journal of Immunology 188, 3522-3531
145. Carmona-Rivera, C. et al. (2014) Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2. Annals of the Rheumatic Diseases 74, 1417-1424
146. Fenton, K. (2014) The effect of cell death in the initiation of lupus nephritis. Clinical and Experimental Immunology 179, 11-16
147. Wang, H. et al. (2015) Neutrophil extracellular trap mitochondrial DNA and its autoantibody in systemic lupus erythematosus and a proof-of-concept trial of metformin. Arthritis and Rheumatology 67, 3190-3200
148. Verthelyi, D. et al. (1998) DNAse treatment does not improve the survival of lupus prone (NZB x NZW)F1 mice. Lupus 7, 223-230
149. Davis, J.C. Jr et al. (1999) Recombinant human Dnase I (rhDNase) in patients with lupus nephritis. Lupus 8, 68-76
150. Ahn, J., Ruiz, P. and Barber, G.N. (2014) Intrinsic self-DNA triggers inflammatory disease dependent on STING. Journal of Immunology 193, 4634-4642
151. Lapponi, M.J. et al. (2013) Regulation of neutrophil extracellular trap formation by anti-inflammatory drugs. Journal of Pharmacology and Experimental Therapeutics 345, 430-437
152. Peer, V. et al. (2016) Renoprotective effects of DNAse-I treatment in a rat model of ischemia/reperfusion-induced acute kidney injury. American Journal of Nephrology 43, 195-205
153. Bakker, P.J. et al. (2015) TLR9 mediates remote liver injury following severe renal ischemia reperfusion. PLoS ONE 10, e0137511
154. Jansen, M.P.B. et al. (2017) Mitochondrial DNA is released in urine of sirs patients with acute kidney injury and correlates with severity of renal dysfunction. Shock 2017 Aug 23. doi: 10.1097/SHK.0000000000000967. [Epub ahead of print]
155. Tsuji, N. et al. (2016) Role of mitochondrial DNA in septic AKI via toll-like receptor 9. Journal of the American Society of Nephrology 27, 2009-2020
156. Atamaniuk, J. et al. (2006) Cell-free plasma DNA: a marker for apoptosis during hemodialysis. Clinical Chemistry 52, 523-526
157. Cichota, L.C. et al. (2015) Circulating double-stranded DNA in plasma of hemodialysis patients and its association with iron stores. Clinical Laboratory 61, 985-990
158. Opatrna, S. et al. (2009) Cell-free plasma DNA during hemodialysis. Renal Failure 31, 475-480
159. Ozkaya, O. et al. (2009) Plasma cell-free DNA levels in children on peritoneal dialysis. Nephron. Clinical Practice 113, c258c261
160. Pajek, J. et al. (2010) Cell-free DNA in the peritoneal effluent of peritoneal dialysis solutions. Therapeutic Apheresis and Dialysis 14, 20-26
161. Virzi, G.M. et al. (2016) Peritoneal cell-free DNA: an innovative method for determining acute cell damage in peritoneal membrane and for monitoring the recovery process after peritonitis. Journal of Nephrology 29, 111-118
162. Korabecna, M. et al. (2012) Alterations in methylation status of immune response genes promoters in cell-free DNA during a hemodialysis procedure. Expert Opinion on Biological Therapy 12(Suppl 1), S27S33
163. Tovbin, D. et al. (2012) Circulating cell-free DNA in hemodialysis patients predicts mortality. Nephrology Dialysis Transplantation 27, 3929-3935
164. Szeto, C.C. et al. (2016) Plasma mitochondrial DNA level is a prognostic marker in peritoneal dialysis patients. Kidney & Blood Pressure Research 41, 402-412
165. Garcia-Olmo, D. and Garcia-Olmo, D.C. (2001) Functionality of circulating DNA: the hypothesis of genometastasis. Annals of the New York Academy of Sciences 945, 265-275
166. Garcia-Olmo, D.C. et al. (2008) Release of cell-free DNA into the bloodstream leads to high levels of non-tumor plasma DNA during tumor progression in rats. Cancer Letters 272, 133-140
167. Garcia-Olmo, D.C. et al. (2013) Quantitation of cell-free DNA and RNA in plasma during tumor progression in rats. Molecular Cancer 12, 8
168. Garcia-Olmo, D. et al. (1999) Tumor DNA circulating in the plasma might play a role in metastasis. The hypothesis of the genometastasis. Histology and Histopathology 14, 1159-1164
169. Simsekyilmaz, S. et al. (2014) Role of extracellular RNA in atherosclerotic plaque formation in mice. Circulation 129, 598-606
170. Fischer, S. et al. (2014) Impact of extracellular RNA on endothelial barrier function. Cell & Tissue Research 355, 635-645
171. Jylhava, J. et al. (2013) Characterization of the role of distinct plasma cell-free DNA species in age-associated inflammation and frailty. Aging Cell 12, 388-397
172. Atamaniuk, J. et al. (2012) Apoptotic cell-free DNA promotes inflammation in haemodialysis patients. Nephrology Dialysis Transplantation 27, 902-905
173. Muzes, G. et al. (2014) Preconditioning with intravenous colitic cell-free DNA prevents DSS-colitis by altering TLR9-associated gene expression profile. Digestive Diseases and Sciences 59, 2935-2946
174. Li, X. et al. (2015) Extracellular, but not intracellular HMGB1, facilitates self-DNA induced macrophage activation via promoting DNA accumulation in endosomes and contributes to the pathogenesis of lupus nephritis. Molecular Immunology 65, 177-188
175. Yusof, F. et al. (2015) Effects of nephrolithiasis on serum DNase (deoxyribonuclease I and II) activity and E3 SUMO-protein ligase NSE2 (NSMCE2) in Malaysian individuals. Biomedical and Environmental Sciences 28, 660-665
176. Jorgez, C.J. et al. (2006) Quantity versus quality: optimal methods for cell-free DNA isolation from plasma of pregnant women. Genetics in Medicine 8, 615-619
177. Kirsch, C. et al. (2008) An improved method for the isolation of free-circulating plasma DNA and cell-free DNA from other body fluids. Annals of the New York Academy of Sciences 1137, 135-139
178. Xue, X. et al. (2009) Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. Clinica Chimica Acta 404, 100-104
179. Sharma, V.K., Vouros, P. and Glick, J. (2011) Mass spectrometric based analysis, characterization and applications of circulating cell free DNA isolated from human body fluids. International Journal of Mass Spectrometry 304, 172-183
180. Breitbach, S. et al. (2014) Direct measurement of cell-free DNA from serially collected capillary plasma during incremental exercise. Journal of Applied Physiology (1985) 117, 119-130
181. Hibi, K. et al. (1998) Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Research 58, 1405-1407
182. Jung, M. et al. (2017) Bisulfite conversion of DNA from tissues, cell lines, buffy coat, FFPE tissues, microdissected cells, swabs, sputum, aspirates, lavages, effusions, plasma, serum, and urine. Methods in Molecular Biology 1589, 139-159
183. Huang, D.J. et al. (2008) Isolation of cell-free DNA from maternal plasma using manual and automated systems. Methods in Molecular Biology 444, 203-208
184. Page, K. et al. (2006) The importance of careful blood processing in isolation of cell-free DNA. Annals of the New York Academy of Sciences 1075, 313-317
185. Fernando, M.R. et al. (2012) Stabilization of cell-free RNA in blood samples using a new collection device. Clinical Biochemistry 45, 1497-1502
186. Hidestrand, M. et al. (2012) Influence of temperature during transportation on cell-free DNA analysis. Fetal Diagnosis and Therapy 31, 122-128
187. Norton, S.E. et al. (2013) A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. Clinical Biochemistry 46, 1561-1565
188. Qin, J., Williams, T.L. and Fernando, M.R. (2013) A novel blood collection device stabilizes cell-free RNA in blood during sample shipping and storage. BMC Research Notes 6, 380
189. El Messaoudi, S. et al. (2013) Circulating cell free DNA: preanalytical considerations. Clinica Chimica Acta 424, 222-230
190. Koide, K. et al. (2005) Fragmentation of cell-free fetal DNA in plasma and urine of pregnant women. Prenatal Diagnosis 25, 604-607
191. Goldshtein, H., Hausmann, M.J. and Douvdevani, A. (2009) A rapid direct fluorescent assay for cell-free DNA quantification in biological fluids. Annals of Clinical Biochemistry 46(Pt 6), 488-494
192. Devonshire, A.S. et al. (2014) Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Analytical and Bioanalytical Chemistry 406, 6499-6512
193. Kraaij, T. et al. (2016) A novel method for high-throughput detection and quantification of neutrophil extracellular traps reveals ROS-independent NET release with immune complexes. Autoimmunity Reviews 15, 577-584
194. Zhong, X.Y. et al. (2007) Is the quantity of circulatory cell-free DNA in human plasma and serum samples associated with gender, age and frequency of blood donations? Annals of Hematology 86, 139-143
195. Polcher, M. et al. (2010) Impact of the menstrual cycle on circulating cell-free DNA. Anticancer Research 30, 2235-2240
196. Jylhava, J. et al. (2011) Aging is associated with quantitative and qualitative changes in circulating cell-free DNA: the vitality 90+ study. Mechanisms of Ageing and Development 132, 20-26
197. Urato, A.C. et al. (2008) Smoking in pregnancy is associated with increased total maternal serum cell-free DNA levels. Prenatal Diagnosis 28, 186-190
198. Atamaniuk, J. et al. (2010) Cell-free plasma DNA and purine nucleotide degradation markers following weightlifting exercise. European Journal of Applied Physiology 110, 695-701
199. Beiter, T. et al. (2011) Short-term treadmill running as a model for studying cell-free DNA kinetics in vivo. Clinical Chemistry 57, 633-636
200. Peters, D.L. and Pretorius, P.J. (2012) Continuous adaptation through genetic communication – a putative role for cell-free DNA. Expert Opinion on Biological Therapy 12(Suppl 1), S127S132
201. Vlkova, B. et al. (2010) Circulating free fetal nucleic acids in maternal plasma and preeclampsia. Medical Hypotheses 74, 1030-1032
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed